Skip to main content

Table 2 Univariate survival analyses according to primary tumor factors and DTC/CTC status

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

  DFSª (n= 211) BCSSb (n= 236) OS (n= 236)c
  HR 95% CI P HR 95% CI P HR 95% CI P
DTC status          
   BM1-pos vs. BM1-neg 1.1 0.7-1.8 0.602 1.0 0.7-1.7 0.857 1.1 0.7-1.7 0.671
   BM2-pos vs. BM2-neg 1.3 0.6-3.1 0.480 1.2 0.5-2.9 0.715 1.2 0.5-2.9 0.715
   BM3-pos vs. BM3-neg 2.3 1.3-3.9 0.003 3.0d 1.8-5.2d < 0.001d 2.8e 1.7-4.7e < 0.001e
cN status (vs. cN0)    0.001    < 0.001    < 0.001
   cN1 2.1 1.3-3.3 0.001 2.3 1.5-3.6 < 0.001 2.2 1.4-3.4 < 0.001
   cN 2-4 2.5 1.4-4.5 0.003 3.0 1.7-5.3 < 0.001 2.8 1.6-4.8 < 0.001
Hormone receptor status          
   PgR-pos vs. PgR-neg 1.6 1.0-2.3 0.034 2.0 1.4-2.8 < 0.001 1.8 1.3-2.6 0.001
   ER-pos vs. ER-neg 1.7 1.2-2.6 0.007 1.9 1.3-2.6 < 0.001 1.8 1.3-2.5 0.001
Histological grade          
   Grade 3 vs. grade 1-2 1.4 1.1-1.7 0.003 1.4 1.2-1.7 0.001 2.0 1.3-3.0 0.001
cT status          
   cT4 vs. cTX-3 1.1 0.7-1.9 0.584 1.3 0.8-2.0 0.226 1.4 0.9-2.1 0.151
CTC status          
   PB1-pos vs. PB1-neg 2.0 0.8-4.8 0.146 2.2f 1.0-4.8f 0.046f 2.1g 1.0-4.6g 0.057g
   PB2 pos vs. PB2-neg 1.8 0.2-13.5 0.551 1.6 0.2-12.0 0.631 1.6 0.2-12.0 0.631
   PB3-pos vs. PB3-neg 1.6 0.5-5.1 0.434 2.0 0.6-6.4 0.258 1.8 0.6-5.9 0.318
Clinical response          
   No CR vs. CR 1.2 0.5-2.9 0.737 1.2 0.5-3.0 0.651 1.2 0.5, 2.9 0.727
  1. ªDisease-free survival (DFS) only for M0 patients.
  2. bBreast cancer specific survival (BCSS) for all patients.
  3. cOverall survival (OS) for all patients.
  4. dBCSS according to bone marrow aspiration at BM3 analyzed for M0 patients only: hazard ratio (HR) 2.6, 95% CI 1.4-4.6, P = 0.002.
  5. eOS according to BM3 status analyzed for stage M0 patients only: HR 2.4, 95% CI 1.4-4.2, P = 0.003.
  6. fBCSS according to peripheral blood sampling at PB1 analyzed for stage M0 patients only: HR 2.1, 95% CI 0.8-5.1, P = .116.
  7. gOS according to PB1 status analyzed for stage M0 patients only: HR 2.0, 95% CI 0.8-4.9, P = 0.142.
  8. BM1, BM2 and BM3: bone marrow aspiration pre-treatment, at surgery, and 12 months after start of neoadjuvant treatment respectively.
  9. cT: clinical tumor status; cN: clinical lymph node status; M0: no metastases present; DTC: disseminated tumor cells; CTC: circulating tumor cells; CR: complete response.